Equity Overview
Price & Market Data
Price: $4.36
Daily Change: -$0.27 / 6.19%
Range: $4.13 - $4.83
Market Cap: $3,121,075
Volume: 80,979
Performance Metrics
1 Week: 1.87%
1 Month: -25.77%
3 Months: -48.10%
6 Months: -60.55%
1 Year: -91.70%
YTD: -60.65%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.